Johnson & Johnson Stock News

Launches S.C.A.L.E 2.0 Strategy With Use of Johnson & Johnson Single Dose Vaccine ABUJA The Minister of Health , Dr Osagie Ehanire has hinted that although the SCALES strategy has proven to be quite effective in ramping up COVID-19 vaccination coverage, but the proportion of fully vaccinated Nigerians is still very low, partly because []

The term fully vaccinated needs to be redefined. Its time for the United States and the CDC to see natural immunity as a partial path to protection The US Centers for Disease Control and Prevention (CDC) has failed to recognize that people with confirmed Covid infections, also known as natural immunity, have achieved some level of protection against subsequent infections and severe disease. This has unnecessarily fueled divisiveness, particularly when vaccines are mandated without acknowledgement that prior Covid is an alternate path, albeit with some limitations, for protection of the individual and helping to build the populations immunity wall. While there has been a body of data supporting a robust immune response to Covid infections, that evidence has recently been substantially bolstered. In the very large trial on the Johnson and Johnson vaccine single shot compared with placebo, among over 2,000 participants with prior infections, as documented by positive antibody status, their protection against moderate or severe disease was 90%.

A Johnson & Johnson subsidiary proposed on Friday that it would submit to an independent examination of the corporate restructuring the healthcare giant undertook in an attempt to settle in U.S. bankruptcy court thousands of lawsuits alleging that J&J baby powder and other talc products cause cancer. Greg Gordon, a lawyer for J&J subsidiary LTL Management LLC, raised during a hearing before U.S. Bankruptcy Judge Michael Kaplan the idea of a court-appointed examiner that could "come in and do whatever investigation it wants" to determine whether the restructuring short-changed cancer victims.

Learn about the origins of Johnson & Johnson and the health care conglomerate''s five largest shareholders.

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ ), has announced results from the Phase 2b QUASAR Induction study of Tremfya (guselkumab) in active ulcerative colitis . The findings were presented at the Congress of the European Crohn''s and Colitis Organization (ECCO). The trial included adult patients with moderately to severely active … Full story available on Benzinga.com

The Janssen Pharmaceutical, a subsidiary of Johnson & Johnson (JNJ), said that the company’s experimental therapy for Crohn’s disease ((CD)), Tremfya led to clinical remission in…

SPRING HOUSE, Pa., Feb. 18, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1. Results showed a significantly greater proportion of adults with moderately to severely active ulcerative colitis (UC) who previously had an inadequate response or intolerance to conventional therapies and/or selected advanced therapies and were treated with TREMFYA ® (guselkumab) achieved clinical response a at week 12, the study''s primary endpoint (intravenous [IV] TREMFYA 200 mg: 61.4 percent [62/101] and IV TREMFYA 400 mg: 60.7 percent [65/107]) compared with placebo (27.6 percent [29/105]). 1 Safety data at week 12 were consistent with the safety profile for TREMFYA in approved indications. 1,2 TREMFYA is not currently approved for the treatment of adults with UC in the U.S. 2 These new efficacy and safety data are the first reported on the investigational use of TREMFYA for moderately to severely active UC in an analysis of 313 patients enrolled in the QUASAR clinical program.

Canada approved, on Thursday, the Novavax COVID-19 vaccine for people aged 18 and over. The announcement makes “Novavax” the fifth COVID-19 vaccine authorized in the country after AstraZeneca, Moderna, Pfizer and Johnson & Johnson. In a news release, Health Canada said the vaccine is 90% effective at preventing symptomatic COVID-19 and 100% effective at preventing […]

Related Stocks: BRK.B , DM , VLY , JNJ , SDY , PNFP , XONE , SLV , VWO ,

Exclusive: chair of standards committee calls for power to shut down APPGs where there are clear conflicts of interest More than £13m has been poured into a growing network of MPs’ interest groups by private firms including healthcare bodies, arms companies and tech giants, fuelling concerns over the potential for backdoor influence. Analysis by the Guardian and Open Democracy found that more than half the total £25m in funding for all-party parliamentary groups (APPGs) since 2018 has come from the private sector. The obesity APPG, which has sought to promote medical interventions for obesity, received £178,500 to £183,000 between 2019 and 2021 from three private healthcare companies that make or promote gastric bands or drugs used in obesity surgery and treatment: Johnson & Johnson, Medtronic and Novo Nordisk. The support was used to pay for a lobbyist, HealthComms Consulting, to run the APPG’s secretariat. The lobbyist says on its website that the APPG promoted calls for “a shift away from the ‘move more, eat less’ mentality prevalent in obesity thinking and better utilisation of treatment for obesity and access to services”.

Novavax now joins Pfizer, Moderna, AstraZeneca and Johnson and Johnson as vaccine makers that have COVID-19 jabs approved for use in Canada.

Novavax now joins Pfizer, Moderna, AstraZeneca and Johnson and Johnson as vaccine makers that have COVID-19 jabs approved for use in Canada.

A Johnson Johnson executive testifying at a bankruptcy trial on Wednesday indicated the company may be willing to increase it settlement offer in talc cases above $2B, but only…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), has partnered with Remix Therapeutics, a biotech company developing small…

DaVita (DVA) said a study suggested that dialysis patients who received Johnson & Johnson''s (JNJ) adenovirus vector-based COVID-19 vaccine were found to have similar rates of…